HIMS vs NVO

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 6. 4% for Novo Nordisk A/S (NVO). Novo Nordisk A/S (NVO) offers the better valuation at 12. 7x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Novo Nordisk A/S (NVO) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

7x versus Hims & Hers Health, Inc. at 52. 7x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 1x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 5%, compared to +39. 0% for Novo Nordisk A/S (NVO). Over 10 years, the gap is even starker: HIMS returned +174. 3% versus NVO's +105. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novo Nordisk A/S (NVO) is the lower-risk stock at 1.

56β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 54% more volatile than NVO relative to the S&P 500. On balance sheet safety, Novo Nordisk A/S (NVO) carries a lower debt/equity ratio of 67% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 6. 4% for Novo Nordisk A/S (NVO). On earnings-per-share growth, the picture is similar: Novo Nordisk A/S grew EPS 1. 8% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus 5. 5% for Hims & Hers Health, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus 5. 2% for HIMS. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2.

1x forward P/E versus 53. 9x for Hims & Hers Health, Inc. — 51. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 10. 4% to $29. 67.

In this comparison, NVO (4.

0% yield) pays a dividend. HIMS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novo Nordisk A/S (NVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (4.

0% yield, +105. 1% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVO: +105. 1%, HIMS: +174. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HIMS is a small-cap high-growth stock; NVO is a large-cap deep-value stock. NVO pays a dividend while HIMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.